A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Recruiting

Phase 2

Celgosivir & PeginterferonA Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Sponsor:

BioWest Therapeutics Inc

Code:

NCT00332176

Conditions

Chronic Hepatitis C

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Celgosivir

Peginterferon alfa 2b + ribavirin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-16. This information was provided to ClinicalTrials.gov by BioWest Therapeutics Inc on 2008-04-08.